#Canon Marketing Japan #Microbiome Science #Metagen Therapeutics

Canon Marketing Japan Invests in Metagen Therapeutics

In a significant step toward integrating innovative microbiome science with healthcare, Canon Marketing Japan, led by CEO Masachika Adachi, has made a strategic investment in Metagen Therapeutics. This company focuses on advancing medical and pharmaceutical applications based on gut microbiome research.

The investment stems from Canon Marketing Japan’s corporate venture capital fund, the Canon Marketing Japan MIRAI Fund. Alongside financial backing, Canon is collaborating with Metagen in the Yamagata Prefecture's initiative known as the "Tsuruoka Gastronomic Innovation Plan". This particular project aims to create a comprehensive health habit database that scientists can use to better understand the influence of local dietary culture on health from the perspective of gut microbiome science.

Understanding Metagen Therapeutics

Founded in January 2020 and headquartered in Tsuruoka City, Yamagata Prefecture, Metagen Therapeutics is pioneering the use of fecal microbiota transplantation (FMT) aimed at restoring healthy gut microbiota in patients through donations. They have established a